ABVC实时信号 | 通过Getagraph.com最大化利润

购买 116596 min ago

@ $1.300

发出时间: 9 Feb 2024 @ 02:07

回报率: 7.78%

上一信号: Feb 7 - 22:30

上一信号: 出售

回报率: -7.80 %

Live Chart Being Loaded With Signals

Commentary (30 Apr 2024 @ 01:21):

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States...

Stats
今日成交量	1.55M
平均成交量	1.09M
市值	14.80M
EPS	$0 ( 2024-03-29 )
下一个收益日期	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.580
ATR14	$0.00900 (0.64%)

Insider Trading

Date	Person	Action	type
2022-05-20	Jiang Shuling	Buy	Common Stock
2021-08-02	An Chihliang	Sell	Common Stock
2021-08-02	Sakamoto Norimi	Buy
2021-08-02	Odaira Yoshinobu	Sell	Common Stock
2021-08-02	Jiang Tsung Shann	Buy	Common Stock

INSIDER POWER
0.00
Last 77 transactions
Buy: 22 119 096 \| Sell: 9 170 000

音量相关性

長: -0.11 (neutral)

短: -0.49 (neutral)

Signal:(64.658) Neutral

AMERICAN BRIVISION 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

AMERICAN BRIVISION 相关性 - 货币/商品

-0.76
( moderate negative )

-0.68
( moderate negative )

0.00
( neutral )

-0.86
( strong negative )

0.73
( moderate )

AMERICAN BRIVISION 财务报表

Annual	2023
营收:	$152 430
毛利润:	$-178 138 (-116.87 %)
EPS:	$-2.43

FY	2023
营收:	$152 430
毛利润:	$-178 138 (-116.87 %)
EPS:	$-2.43

FY	2022
营收:	$969 783
毛利润:	$683 368 (70.47 %)
EPS:	$-5.15

FY	2021
营收:	$355 797
毛利润:	$350 711 (98.57 %)
EPS:	$-0.510

Financial Reports:

No articles found.

AMERICAN BRIVISION

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage. It has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.